Abstract
Introduction: Elevated cardiac troponin (cTn) levels are associated with adverse events in patients with chronic and acute decompensated heart failure. Neopterin,a moderator of cellular immune response, predicts future cardiac and vascular adverse events in patients with chronic coronary artery disease. Hypothesis: The aim of this study was to evaluate the prognostic value of neopterin in the setting of acute heart failure by itself and in relation to troponin. Methods: The biomarkers in AHF (BACH trial) was a prospective,15 center, international study of 1641 patients presenting to the ED with dyspnea.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
